International Society of Urological Pathology Multidisciplinary Expert Consultation Conference on Evaluation of Treatment Effects in Prostate and Bladder Cancer
Abstract
Treatment effects in the urinary bladder are variable and range from localized post-transurethral resection changes to widespread systemic therapy effects. The International Society of Urological Pathology (ISUP) organized a consensus meeting in Vienna, Austria, in September 2025, focused on the evaluation of treatment effects in both the prostate and bladder. Working Group 2 was assigned the topic of the urinary bladder, and a group of pathologists and clinicians was convened. They worked cooperatively to develop a 30-question, premeeting survey for the ISUP membership, which covered the following topics: systemic therapy-related changes, intravesical therapy and radiotherapy-related changes, macroscopic examination and reporting of treated bladder specimens, and relevant ancillary testing methods for grossly residual and/or minimal residual disease. The premeeting survey results highlighted uncertainty about tumor regression grading (TRG), variability in reporting practices for post-resection and intravesical therapy cases, and divergent opinions on the potential utility of molecular testing. Based on findings from this crowd-sourced experience, the Working Group researched the primary medical literature to study the problematic premeeting survey topics, curated focused presentations of published experience for the consensus meeting participants and developed refined consensus questions for consensus voting. Consensus was achieved in 18/19 polling statements. Use of molecular tests to distinguish benign mimickers from carcinoma did not reach consensus. Overall, the surveys and in-person consensus voting supported standardized reporting practices and terminology for post-therapy cases, interdisciplinary development of a bladder TRG scheme, and the utility of select molecular and immunohistochemical testing in the post-treatment setting.
// Source
Authors: Michelle R. Downes, Sara E. Wobker, Steven C. Smith, Markus Eckstein, Mahmut Akgul, Dilek E. Baydar, Fadi Brimo, E. Compérat, Arndt Hartmann, Ashish M. Kamat, Anandi Lobo, Maria R. Raspollini, Ankur R. Sangoi, Shahrokh F. Shariat, T. Tsuzuki, Bas W. G. van Rhijn, Sean R. Williamson, Geert J. L. H. van Leenders, Liang Cheng, Antonio Lopez-Beltran, the Members of ISUP GU Cancer Treatment Effects Consensus Panel
Institutions: Brigham and Women's Hospital, Leiden University Medical Center, Brown University, University of North Carolina at Chapel Hill, University of Virginia, McGill University Health Centre, Cornell University, University of Toronto, Friedrich-Alexander-Universität Erlangen-Nürnberg, Azienda Ospedaliero-Universitaria Careggi, Universitätsklinikum Erlangen, The University of Texas MD Anderson Cancer Center, Stanford Medicine, Koç University, The University of Texas Southwestern Medical Center, Al-Ahliyya Amman University, Medical University of Vienna, Erasmus MC Cancer Institute, University of Córdoba, Aichi Medical University, Cleveland Clinic, All India Institute of Medical Sciences Raipur, The Netherlands Cancer Institute, Comprehensive Cancer Center Erlangen, Comprehensive Cancer Center Vienna, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Precision Therapeutics (United States)